<DOC>
	<DOCNO>NCT01558453</DOCNO>
	<brief_summary>The purpose study determine pediatric neoplastic response chemotherapy propose evaluate sensitivity oxaliplatin immunohistochemistry ERCC-1 expression analysis .</brief_summary>
	<brief_title>Oxaliplatin Children With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Age ≤ 21 year old time cancer diagnosis . 2 . Confirmed histological diagnosis every patient , except brain tumor , optic pathway glioma , one follow histological diagnosis : Ewing´s sarcoma/PNET Osteosarcoma Soft tissue sarcoma/rhabdomyosarcoma Wilms tumor Neuroblastoma Retinoblastoma Low grade astrocytoma High grade astrocytoma/GBM Ependymoma Germ cell tumor Other rare tumor hepatocellular carcinoma , pediatric colorectal carcinoma , renal cell carcinoma , adrenocortical carcinoma nasopharyngeal carcinoma . 3 . All subject measurable disease , least one dimension , 20mm minimum , presence neoplastic cell cephalorachidian fluid . 4 . All patient must life expectancy ≥ 8 week , PS Karnofsky ≥50 patient ≥ 10 year old PS Lansky ≥50 patient &lt; 10 year old . 5 . Previous treatment : least 3 week without chemotherapy . least 6 month spine brain radiation . allow corticosteroid patient CNS tumor , recommend stable dos reduce dose 7 day protocol treatment . there´s limit drug chemotherapy use previously , except oxaliplatin . 6 . Adequate function define : Hematologic : neutrophil &gt; 1000/mm³ , platelet &gt; 75000/mm³ hemoglobin &gt; 8 g/dL . Renal creatinine accord : Age ≤ 5 ano Cr ≤ 0,8 mg/dL 5 &lt; age &lt; 10 Cr ≤ 1,0 mg/dL 10 &lt; age ≤ 15 Cr ≤ 1,2 mg/dL &gt; 15 year Cr ≤ 1,5 mg/dL Hepatic : total bilirubin ≤ 3 mg/dL . Neurologic : patient seizure control . 7 . Legal representative ( father , mother tutor ) subject ( &gt; 18 year old ) must sign date Informed Consent Form ( ICF ) , inform relevant aspect regard study participation . 8 . For female patient childbearing age : Presence negative pregnancy test within 7 day prior day 0 . 9 . Patient must agree use effective contraception procreative potential exists . Use reliable mean contraception ( e.g . hormonal contraceptive , patch , vaginal ring , intrauterine device , physical barrier , abstinence ) subject reproductive potential ( male female ) require study treatment 3 month follow last dose study drug 10 . It known curative treatment option prove therapy increase survival quality life . 1 . Oxaliplatin previous use . 2 . Another chemotherapy experimental drug , simultaneously . 3 . If female , pregnant lactating . 4 . Active infection . 5 . Any serious existent condition could affect , adverse way , subjet 's capacity treat accord protocol . 6 . Any condition , therapy , medical condition , , opinion attend physician could represent risk patient adversely affect study objective . 7 . Use investigational drug &lt; 30 day enter study . 8 . Medical history : severe renal insufficiency ; know hypersensitiveness platine ; myelosuppression ; peripheral sensory neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>